lovastatin has been researched along with Rhabdomyosarcoma, Embryonal in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asperti, M; Bernardi, S; Cassandri, M; Codenotti, S; Fanzani, A; Gastaldello, S; Giacomini, A; Mandracchia, D; Marampon, F; Mignani, L; Mitola, S; Monti, E; Parolini, S; Poli, M; Rezzola, S; Rota, R; Russo, D; Tabellini, G; Tomasini, D; Triggiani, L; Vezzoli, M; Zizioli, D | 1 |
1 other study(ies) available for lovastatin and Rhabdomyosarcoma, Embryonal
| Article | Year |
|---|---|
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors.
Topics: Animals; Child; Deoxyglucose; DNA Repair; DNA-Activated Protein Kinase; Doxorubicin; Glucose; Glycolysis; Hexokinase; Histones; Humans; Ki-67 Antigen; Lovastatin; Mevalonic Acid; MTOR Inhibitors; Oxidoreductases; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Proto-Oncogene Proteins c-akt; Rhabdomyosarcoma, Embryonal; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; TOR Serine-Threonine Kinases; Zebrafish | 2022 |